• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Avacopan non-inferior to prednisone in the treatment of ANCA-associated vasculitis

bySze Wah Samuel ChanandHarsh Shah
February 17, 2021
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. For the treatment of ANCA-associated vasculitis, avacopan was non-inferior to prednisone taper for the number of remissions at week 26.

2. Avacopan was superior to prednisone taper for sustained remission at week 52.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a life-threatening vasculitis. The current standard of care treatments for patients includes cyclophosphamide or rituximab and a prednisone regimen. One of the disease mechanisms is the activation of the alternative complement system, and avacopan is a C5a receptor antagonist. In this study, patients with ANCA-associated vasculitis were randomized either to avacopan or a prednisone taper. The patients were scored according to the Birmingham Vasculitis Activity Score (BVAS). Remission was defined as score of 0. At week 26, avacopan was non-inferior to prednisone taper for the number of remissions. At week 52, avacopan was superior to prednisone. Serious adverse events, not related to vasculitis worsening, was similar between both groups. Limitations in the trial included that steroids were used in the avacopan group, which was about one third the dose of the prednisone group. Overall, this trial demonstrated that avacopan is an option for the treatment of ANCA-associated vasculitis as opposed to prednisone for patients who have an indication for cyclophosphamide or rituximab.

Click here to read the study in the NEJM

Relevant Reading: Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

In-Depth [ randomized controlled trial]: This was a phase 3, randomized, placebo-controlled trial of 331 patients randomized to either avacopan or prednisone. Eligible patients included those with ANCA-associated vasculitis with an indication for cyclophosphamide or rituximab, including newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis. Patients who received more than three grams of intravenous glucocorticoids within four weeks were excluded from the study. All patients received either cyclophosphamide or rituximab. The first primary endpoint was remission defined by a BVAS score of 0 at week 26. Avacopan (72.3%) was non-inferior to prednisone taper (70.1%) at week 26 (95% confidence interval [CI], -6.0 to 12.8, P < 0.001 for noninferiority; P = 0.24 for superiority). Avacopan (65.7%) was superior to prednisone taper (54.9%) at week 52 for sustained remission (95% CI, 2.6 to 22.3, P = 0.007 for superiority). Serious adverse events, not related to vasculitis-worsening, were similar between both groups (avacopan, 37.3; prednisone taper, 39.0%). Adverse events potentially related to glucocorticoid use were more frequent in the prednisone group (80.5%) compared to the treatment group (66.3%; difference, -14.2 percentage points; 95% CI, -23.7 to -3.8). Overall, avacopan is an appropriate alternative to prednisone taper in the treatment regimen for ANCA-associated vasculitis that may reduce steroid adverse events without any significant increase in infections.

RELATED REPORTS

Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ANCA-associated vasculitisavacopanprednisonerheumatology
Previous Post

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

Next Post

Bimekizumab is tolerable and efficacious for patients with moderate to severe plaque psoriasis

RelatedReports

Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis
Chronic Disease

Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

March 16, 2023
Blindness and visual impairment decreasing worldwide
Chronic Disease

Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage

February 1, 2023
Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

January 24, 2023
Chronic Disease

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

December 13, 2022
Next Post
Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Bimekizumab is tolerable and efficacious for patients with moderate to severe plaque psoriasis

Combined MRI and NIH stroke scores may predict stroke prognosis

Maternal chronic conditions increase risk of cerebral palsy among offspring

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Progression of COVID-19 reduced after high-titer convalescent plasma administration

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Childhood maltreatment may cause mental health problems
  • #VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
  • Metformin use may decrease risk of osteoarthritis development
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options